MedTrace Logo

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

NCT00596804 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2021-08-18

No results posted yet for this study

Summary

This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.

Conditions

  • Non-Hodgkin's Lymphoma
  • Lymphoma, Diffuse
  • Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic

Interventions

DRUG

veltuzumab

once weekly intravenous dosing for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • William Wegener, MD, PhD · Gilead Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00596804 on ClinicalTrials.gov